Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 1
1967 1
1968 2
1969 1
1971 2
1972 1
1973 1
1974 2
1977 1
1989 2
1993 1
1994 3
1997 1
1999 1
2001 2
2002 2
2005 4
2006 1
2009 3
2010 4
2011 4
2014 2
2015 2
2016 5
2019 5
2020 1
2021 1
2022 1
2023 1
2024 4
2025 1
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses.
Papi A, Alfano F, Bigoni T, Mancini L, Mawass A, Baraldi F, Aljama C, Contoli M, Miravitlles M. Papi A, et al. Arch Bronconeumol. 2024 May;60(5):269-278. doi: 10.1016/j.arbres.2024.03.010. Epub 2024 Mar 18. Arch Bronconeumol. 2024. PMID: 38555190 Free article. English, Spanish.
INTRODUCTION: N-acetylcysteine (NAC) is a mucolytic agent with antioxidant properties. Oxidative stress is a key pathogenic mechanism in chronic respiratory conditions such as COPD and chronic bronchitis (CB). ...A similar trend was obser …
INTRODUCTION: N-acetylcysteine (NAC) is a mucolytic agent with antioxidant properties. Oxidative stress is a key pathogenic me …
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Cazzola M, et al. Eur Respir Rev. 2015 Sep;24(137):451-61. doi: 10.1183/16000617.00002215. Eur Respir Rev. 2015. PMID: 26324807 Free PMC article. Review.
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis and chronic obstructive pulmonary disease (COPD), we have carried out a meta-analysis testing the av …
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis …
Effect of Orally Administered N-Acetylcysteine on Chronic Bronchitis: A Meta-analysis.
Wei J, Pang CS, Han J, Yan H. Wei J, et al. Adv Ther. 2019 Dec;36(12):3356-3367. doi: 10.1007/s12325-019-01111-4. Epub 2019 Oct 9. Adv Ther. 2019. PMID: 31598901
INTRODUCTION: The effect of N-acetylcysteine (NAC) treatment for patients with chronic bronchitis (CB) is controversial. ...
INTRODUCTION: The effect of N-acetylcysteine (NAC) treatment for patients with chronic bronchitis (CB) is contro …
Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P, Sathananthan K, Fortescue R. Poole P, et al. Cochrane Database Syst Rev. 2019 May 20;5(5):CD001287. doi: 10.1002/14651858.CD001287.pub6. Cochrane Database Syst Rev. 2019. PMID: 31107966 Free PMC article.
BACKGROUND: Individuals with chronic bronchitis or chronic obstructive pulmonary disease (COPD) may suffer recurrent exacerbations with an increase in volume or purulence of sputum, or both. ...SELECTION CRITERIA: We included rando …
BACKGROUND: Individuals with chronic bronchitis or chronic obstructive pulmonary disease (COPD …
Efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Ohnishi H, Tanimoto T, Inaba R, Eitoku M. Ohnishi H, et al. Respir Investig. 2024 Nov;62(6):1168-1175. doi: 10.1016/j.resinv.2024.10.004. Epub 2024 Oct 15. Respir Investig. 2024. PMID: 39413571
BACKGROUND: The efficacy and safety of mucolytics in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis or exacerbations of COPD have been reported. We conducted a systematic review and meta-an …
BACKGROUND: The efficacy and safety of mucolytics in patients with chronic obstructive pulmonary disease (COP …
The precision medicine strategy to treat COPD pulmonary traits in clinical practice: The role of N-acetylcysteine.
Scioscia G, Baraldi F, Bigoni T, Papi A, Vatrella A, Micheletto C, Foschino Barbaro MP. Scioscia G, et al. Respir Med. 2024 Dec;235:107865. doi: 10.1016/j.rmed.2024.107865. Epub 2024 Nov 15. Respir Med. 2024. PMID: 39549856 Review.
Chronic obstructive pulmonary disease (COPD) is a progressive lung condition and a leading cause of physical decline and death. ...N-acetylcysteine (NAC), a widely used mucolytic agent, might be a major player in this strategy. ...
Chronic obstructive pulmonary disease (COPD) is a progressive lung condition and a leading cause of physi …
Efficacy and Safety of N-Acetylcysteine for Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
Zhang L, Xiong Y, Du L. Zhang L, et al. Biomed Res Int. 2022 Jun 26;2022:9133777. doi: 10.1155/2022/9133777. eCollection 2022. Biomed Res Int. 2022. Retraction in: Biomed Res Int. 2023 Nov 29;2023:9816263. doi: 10.1155/2023/9816263. PMID: 35795313 Free PMC article. Retracted. Clinical Trial.
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis are associated with poor clinical outcomes. ...High-dose NAC has no marked clinical benefits for COPD patients with concurrent …
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis …
Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, van Schayck O, van Weel C. Schermer T, et al. Respir Med. 2009 Apr;103(4):542-51. doi: 10.1016/j.rmed.2008.11.003. Epub 2009 Jan 9. Respir Med. 2009. PMID: 19138505 Free article. Clinical Trial.
BACKGROUND: Increased oxidative stress and bronchial inflammation are important mechanisms in the pathophysiology of COPD. AIM: To investigate whether treatment with the inhaled corticosteroid fluticasone propionate (FP) or the anti-oxidative agent N-acetylcystei …
BACKGROUND: Increased oxidative stress and bronchial inflammation are important mechanisms in the pathophysiology of COPD. AIM: To in …
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections.
Blasi F, Page C, Rossolini GM, Pallecchi L, Matera MG, Rogliani P, Cazzola M. Blasi F, et al. Respir Med. 2016 Aug;117:190-7. doi: 10.1016/j.rmed.2016.06.015. Epub 2016 Jun 16. Respir Med. 2016. PMID: 27492531 Free article. Review.
The aim of this review is to examine current evidence for the use of N-acetylcysteine (NAC) in the treatment of biofilm-related respiratory infections. METHODS: Electronic searches of PUBMED up to September 2015 were conducted, searching for 'biofilm', 'respiratory …
The aim of this review is to examine current evidence for the use of N-acetylcysteine (NAC) in the treatment of biofilm-relate …
63 results